Health Trials

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

ConditionsAdvanced Malignant Solid NeoplasmAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Locally Advanced Malignant Solid NeoplasmMalignant Female Reproductive System NeoplasmMetastatic HER2-Negative Breast CarcinomaMetastatic Malignant Solid NeoplasmRecurrent Endometrial CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Malignant Female Reproductive System NeoplasmRecurrent Malignant Solid NeoplasmRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaUnresectable HER2-Negative Breast CarcinomaUnresectable Malignant Solid Neoplasm
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorNational Cancer Institute (NCI)

About this trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.

Eligibility criteria

Qualifiers

Patient must have measurable disease

Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status between 0-2 OR patient must have Lansky performance status of >= 50% or Karnofsky performance status of >= 50%

Patient must be deemed potentially eligible for a ComboMATCH Treatment Trial as assessed by the enrolling provider

All patients must have sequencing results available from a National Cancer Institute (NCI) credentialed Designated Laboratory (DL)

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Alpelisib
  • Binimetinib
  • Biopsy Procedure
  • Biospecimen Collection
  • Bone Marrow Aspiration
  • Bone Marrow Biopsy
  • Bone Scan
  • Computed Tomography
  • Echocardiography Test
  • Fluorouracil
  • Fulvestrant
  • Ipatasertib
  • Leucovorin
  • Magnetic Resonance Imaging
  • Multigated Acquisition Scan
  • Mutation Carrier Screening
  • Neratinib Maleate
  • Nilotinib Hydrochloride Monohydrate
  • Olaparib
  • Oxaliplatin
  • Paclitaxel
  • Palbociclib
  • Panitumumab
  • Positron Emission Tomography
  • Selumetinib Sulfate
  • Sotorasib

Treatment groups

2,900 Participants
are divided into 20 treatment groups

20

Treatment groups

See each treatment group below.

Locations

481
Puerto Rico
Puerto Rico Hematology Oncology Group00961, Bayamón Puerto Rico
Doctors Cancer Center00674, Manati Puerto Rico
Centro Comprensivo de Cancer de UPR00927, San Juan Puerto Rico
PROncology00927, San Juan Puerto Rico

Sponsors and collaborators

National Cancer Institute (NCI)

Lead sponsor

Source ClinicalTrials.gov